Showing results (361-370 of 457) with videos related to

Sort By:
Pageof 46
The Lancet. Oncology|September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Howard I Scher, Arturo Molina, et al.
JCO Precision Oncology|May 29, 2020
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 InhibitorsEmmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, et al.
Minerva Urology and Nephrology|December 13, 2022
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA ScoreGiuseppe Fornarini, Sara E Rebuzzi, Sebastiano Buti, et al.
Critical Reviews in Oncology/Hematology|August 30, 2008
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approachJohn M Fitzpatrick, John Anderson, Cora N Sternberg, et al.
European Urology|August 22, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 TrialRonald de Wit, David J Vaughn, Yves Fradet, et al.
Cancer Medicine|November 11, 2024
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysisMotohide Uemura, Hiroaki Kikukawa, Yasuhiro Hashimoto, et al.
European Urology|August 2, 2016
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyTomasz M Beer, Andrew J Armstrong, Dana Rathkopf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial CancerDavid J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
The Oncologist|April 3, 2019
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract CancerAristotelis Bamias, Kimon Tzannis, Christina Bamia, et al.
Cells|January 11, 2022
Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell CarcinomaStephane Oudard, Nadine Benhamouda, Bernard Escudier, et al.
Pageof 46